Pam3CSK4 As a Second Hit in NLRP3‐Dependent Activation of Monocytes Primed With Antiphospholipid Antibodies
European Journal of Immunology · 2026-07 · 56 (7)
DOI: 10.1002/eji.70245 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 22.07.2026. Verfasst von Anush Martirosyan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology, National Academy of Sciences, Yerevan, Armenia. Hauptthemen laut MEDLINE: Monocytes, NLR Family, Pyrin Domain-Containing 3 Protein, Antibodies, Antiphospholipid, Lipopeptides. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Committee of Science MES RA, the Ministry of Health of the Czech Republic, the European Regional Development Fund-Project.
Abstract (Originalsprache)
Antiphospholipid antibodies (aPL) are drivers of inflammation and thrombosis in antiphospholipid syndrome (APS). However, the molecular mechanisms underlying infection‐induced exacerbation of APS remain incompletely understood. To identify novel pathways contributing to the pro‐inflammatory and pro‐coagulant activation of monocytes in APS, we screened fourteen Toll‐like receptor (TLR) ligands for their ability to induce tissue factor (TF) expression in a monocyte‐like cell line (THP‐1). Among these, Pam3CSK4, a synthetic TLR1/2 ligand, emerged as a potent inducer of TF in the presence of aPL. Subsequent experiments revealed that Pam3CSK4 synergized with aPL to amplify both TF expression and IL‐1β secretion. This synergistic effect was mediated via NF‐κB signaling and required activation of the NLRP3 inflammasome. aPL priming promoted ATP release, providing the second signal for NLRP3 activation. Inhibition of NLRP3 markedly reduced Pam3CSK4‐induced TF expression, suggesting a critical role for inflammasome signaling in monocyte procoagulant responses. These in vitro findings were confirmed in a mouse model of APS, supporting the pathogenic relevance of the TLR1/2–NLRP3 axis in vivo. Taken together, our results validate the “second hit” paradigm in APS and suggest a novel TLR1/2–NLRP3 axis as a key mediator of infection‐driven inflammatory and thrombotic responses in aPL‐primed monocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology, National Academy of Sciences, Yerevan, Armenia.
- Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- Laboratory of Cell Biology and Virology, Institute of Molecular Biology, National Academy of Sciences, Yerevan, Armenia.
Förderung
- State Committee of Science MES RA
- the Ministry of Health of the Czech Republic
- the European Regional Development Fund-Project
- the European Union
Zitieren
APA
Martirosyan, A., Kriegova, E., Ulehlova, J., Karalyan, Z., Papajik, T., & Manukyan, G. (2026). Pam3CSK4 As a Second Hit in NLRP3‐Dependent Activation of Monocytes Primed With Antiphospholipid Antibodies. European Journal of Immunology, 56(7). https://doi.org/10.1002/eji.70245
Vancouver
Martirosyan A, Kriegova E, Ulehlova J, Karalyan Z, Papajik T, Manukyan G. Pam3CSK4 As a Second Hit in NLRP3‐Dependent Activation of Monocytes Primed With Antiphospholipid Antibodies. European Journal of Immunology. 2026;56(7). doi:10.1002/eji.70245
BibTeX
@article{Martirosyan2026,
author = {Martirosyan, Anush and Kriegova, Eva and Ulehlova, Jana and Karalyan, Zaven and Papajik, Tomas and Manukyan, Gayane},
title = {Pam3CSK4 As a Second Hit in NLRP3‐Dependent Activation of Monocytes Primed With Antiphospholipid Antibodies},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {7},
doi = {10.1002/eji.70245}
}
EUVIMED